These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 29765319)

  • 1. Progression and Regression of Hepatic Lesions in a Mouse Model of NASH Induced by Dietary Intervention and Its Implications in Pharmacotherapy.
    Ding ZM; Xiao Y; Wu X; Zou H; Yang S; Shen Y; Xu J; Workman HC; Usborne AL; Hua H
    Front Pharmacol; 2018; 9():410. PubMed ID: 29765319
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Progression of non-alcoholic steatosis to steatohepatitis and fibrosis parallels cumulative accumulation of danger signals that promote inflammation and liver tumors in a high fat-cholesterol-sugar diet model in mice.
    Ganz M; Bukong TN; Csak T; Saha B; Park JK; Ambade A; Kodys K; Szabo G
    J Transl Med; 2015 Jun; 13():193. PubMed ID: 26077675
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Obeticholic acid protects against hepatocyte death and liver fibrosis in a murine model of nonalcoholic steatohepatitis.
    Goto T; Itoh M; Suganami T; Kanai S; Shirakawa I; Sakai T; Asakawa M; Yoneyama T; Kai T; Ogawa Y
    Sci Rep; 2018 May; 8(1):8157. PubMed ID: 29802399
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Translational Mouse Model for NASH with Advanced Fibrosis and Atherosclerosis Expressing Key Pathways of Human Pathology.
    van den Hoek AM; Verschuren L; Worms N; van Nieuwkoop A; de Ruiter C; Attema J; Menke AL; Caspers MPM; Radhakrishnan S; Salic K; Kleemann R
    Cells; 2020 Sep; 9(9):. PubMed ID: 32883049
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The LXR inverse agonist SR9238 suppresses fibrosis in a model of non-alcoholic steatohepatitis.
    Griffett K; Welch RD; Flaveny CA; Kolar GR; Neuschwander-Tetri BA; Burris TP
    Mol Metab; 2015 Apr; 4(4):353-7. PubMed ID: 25830098
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Docosahexaenoic acid blocks progression of western diet-induced nonalcoholic steatohepatitis in obese Ldlr-/- mice.
    Lytle KA; Wong CP; Jump DB
    PLoS One; 2017; 12(4):e0173376. PubMed ID: 28422962
    [TBL] [Abstract][Full Text] [Related]  

  • 7. TRIF Differentially Regulates Hepatic Steatosis and Inflammation/Fibrosis in Mice.
    Yang L; Miura K; Zhang B; Matsushita H; Yang YM; Liang S; Song J; Roh YS; Seki E
    Cell Mol Gastroenterol Hepatol; 2017 May; 3(3):469-483. PubMed ID: 28462384
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Obese diet-induced mouse models of nonalcoholic steatohepatitis-tracking disease by liver biopsy.
    Kristiansen MN; Veidal SS; Rigbolt KT; Tølbøl KS; Roth JD; Jelsing J; Vrang N; Feigh M
    World J Hepatol; 2016 Jun; 8(16):673-84. PubMed ID: 27326314
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hepatic histopathology of morbid obesity: concurrence of other forms of chronic liver disease.
    Liew PL; Lee WJ; Lee YC; Wang HH; Wang W; Lin YC
    Obes Surg; 2006 Dec; 16(12):1584-93. PubMed ID: 17217634
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metabolic and hepatic effects of liraglutide, obeticholic acid and elafibranor in diet-induced obese mouse models of biopsy-confirmed nonalcoholic steatohepatitis.
    Tølbøl KS; Kristiansen MN; Hansen HH; Veidal SS; Rigbolt KT; Gillum MP; Jelsing J; Vrang N; Feigh M
    World J Gastroenterol; 2018 Jan; 24(2):179-194. PubMed ID: 29375204
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Seven weeks of Western diet in apolipoprotein-E-deficient mice induce metabolic syndrome and non-alcoholic steatohepatitis with liver fibrosis.
    Schierwagen R; Maybüchen L; Zimmer S; Hittatiya K; Bäck C; Klein S; Uschner FE; Reul W; Boor P; Nickenig G; Strassburg CP; Trautwein C; Plat J; Lütjohann D; Sauerbruch T; Tacke F; Trebicka J
    Sci Rep; 2015 Aug; 5():12931. PubMed ID: 26263022
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Liver injury and fibrosis induced by dietary challenge in the Ossabaw miniature Swine.
    Liang T; Alloosh M; Bell LN; Fullenkamp A; Saxena R; Van Alstine W; Bybee P; Werling K; Sturek M; Chalasani N; Masuoka HC
    PLoS One; 2015; 10(5):e0124173. PubMed ID: 25978364
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mitochondrial gene polymorphisms alter hepatic cellular energy metabolism and aggravate diet-induced non-alcoholic steatohepatitis.
    Schröder T; Kucharczyk D; Bär F; Pagel R; Derer S; Jendrek ST; Sünderhauf A; Brethack AK; Hirose M; Möller S; Künstner A; Bischof J; Weyers I; Heeren J; Koczan D; Schmid SM; Divanovic S; Giles DA; Adamski J; Fellermann K; Lehnert H; Köhl J; Ibrahim S; Sina C
    Mol Metab; 2016 Apr; 5(4):283-295. PubMed ID: 27069868
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The FATZO mouse, a next generation model of type 2 diabetes, develops NAFLD and NASH when fed a Western diet supplemented with fructose.
    Sun G; Jackson CV; Zimmerman K; Zhang LK; Finnearty CM; Sandusky GE; Zhang G; Peterson RG; Wang YJ
    BMC Gastroenterol; 2019 Mar; 19(1):41. PubMed ID: 30885145
    [TBL] [Abstract][Full Text] [Related]  

  • 15. INT-767 improves histopathological features in a diet-induced
    Roth JD; Feigh M; Veidal SS; Fensholdt LK; Rigbolt KT; Hansen HH; Chen LC; Petitjean M; Friley W; Vrang N; Jelsing J; Young M
    World J Gastroenterol; 2018 Jan; 24(2):195-210. PubMed ID: 29375205
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diabetes is a progression factor for hepatic fibrosis in a high fat fed mouse obesity model of non-alcoholic steatohepatitis.
    Lo L; McLennan SV; Williams PF; Bonner J; Chowdhury S; McCaughan GW; Gorrell MD; Yue DK; Twigg SM
    J Hepatol; 2011 Aug; 55(2):435-44. PubMed ID: 21184785
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Neovascularization aggravated hepatic fibrosis in combined hypoxia NASH rat model].
    Liu J; Wu W; Gu DH; Liu CY; Dong Q; Yao YL; Wang CS; Chen XP; Yang HX
    Zhonghua Gan Zang Bing Za Zhi; 2017 Jul; 25(7):517-522. PubMed ID: 29055990
    [No Abstract]   [Full Text] [Related]  

  • 18. Liraglutide improves hepatic steatosis and metabolic dysfunctions in a 3-week dietary mouse model of nonalcoholic steatohepatitis.
    Duparc T; Briand F; Trenteseaux C; Merian J; Combes G; Najib S; Sulpice T; Martinez LO
    Am J Physiol Gastrointest Liver Physiol; 2019 Oct; 317(4):G508-G517. PubMed ID: 31460789
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Superior reductions in hepatic steatosis and fibrosis with co-administration of a glucagon-like peptide-1 receptor agonist and obeticholic acid in mice.
    Jouihan H; Will S; Guionaud S; Boland ML; Oldham S; Ravn P; Celeste A; Trevaskis JL
    Mol Metab; 2017 Nov; 6(11):1360-1370. PubMed ID: 29107284
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Non-alcoholic steatohepatitis in children.
    Nanda K
    Pediatr Transplant; 2004 Dec; 8(6):613-8. PubMed ID: 15598336
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.